Nebenwirkungen · Tecfidera
Tecfidera 120 mg gastro-resistant hard capsules Tecfidera 240 mg gastro-resistant hard capsules · Abschnitt 4.8 · PDF-Seite 9–10
HOS-127595 · Präparat HOS-096433
9 MedDRA system organ class Adverse reaction Frequency category Nausea Very common Abdominal pain upper Very common Abdominal pain Very common Vomiting Common Dyspepsia Common Gastritis Common Gastrointestinal disorder Common Hepatobiliary disorders Aspartate aminotransferase increased Common Alanine aminotransferase increased Common Drug-induced liver injury Rare Skin and subcutaneous tissue Pruritus Common disorders Rash Common Erythema Common Alopecia Common Renal and urinary disorders Proteinuria Common General disorders and Feeling hot Common administration site conditions Investigations Ketones measured in urine Very common Albumin urine present Common White blood cell count decreased Common
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-01-06T16:30:00Z · SHA-256 c529e0432acf9767ce48e42408ea2f72e957004be1c6f8e00714d8bd22b2a5fe · Passage d48fec656f58415056e165ea9930d22e309394534d208c0fcc1e061b3e1414c5 · Zeichen 3616–5465 im Abschnitt